Regencell Bioscience Holdings Limited

NasdaqCM RGC

Regencell Bioscience Holdings Limited EPS (Diluted) for the year ending June 30, 2024: USD -0.33

Regencell Bioscience Holdings Limited EPS (Diluted) is USD -0.33 for the year ending June 30, 2024, a 26.67% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

Regencell Bioscience Holdings Limited EPS (Diluted) for the year ending June 30, 2023 was USD -0.45, a 21.05% change year over year.
Regencell Bioscience Holdings Limited EPS (Diluted) for the year ending June 30, 2022 was USD -0.57, a -418.18% change year over year.
Regencell Bioscience Holdings Limited EPS (Diluted) for the year ending June 30, 2021 was USD -0.11, a -71.07% change year over year.
Regencell Bioscience Holdings Limited EPS (Diluted) for the year ending June 30, 2020 was USD -0.06, a -108.09% change year over year.

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Shares (Basic, Weighted)	Revenue

NasdaqCM: RGC

Regencell Bioscience Holdings Limited

CEO	Mr. Yat-Gai Au
IPO Date	July 16, 2021
Location	Hong Kong
Headquarters	First Commercial Building
Employees	12
Sector	Health Care
Industries Biotechnology Pharmaceuticals Research & Consulting

Description

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Key trends

Past 5 years